Litigation Details for Gilead Sciences, Inc. v. Apotex Inc. (D. Del. 2022)

Gilead Sciences, Inc. v. Apotex Inc. (D. Del. 2022)

Docket		Date Filed	2022-10-25
Court	District Court, D. Delaware	Date Terminated	2025-02-18
Cause	35:271 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Patents	10,039,718; 10,786,518
Link to Docket	External link to docket

Details for Gilead Sciences, Inc. v. Apotex Inc. (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-10-25				External link to document
2022-10-25	1	Complaint	U.S. Patent No. 10,039,718 (the “’718 patent”) and U.S. Patent No. 10,786,518 (the “’518 patent”) (together…expiration of the ’718 patent, ’518 patent, ’396 patent, ’473 patent, and ’100 patent (including such actions…infringement of the ’718 patent, ’518 patent, ’396 patent, ’473 patent, and ’100 patent under 35 U.S.C. §§ …expiration date of the ’718 patent, ’518 patent, ’396 patent, ’473 patent, and ’100 patent including any extensions…claims of the ’718 patent, ’518 patent, ’396 patent, ’473 patent, and ’100 patent; E) A	External link to document
2022-10-25	23	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,039,718; 9,428,473; 9,115,… 25 October 2022 1:22-cv-01399 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2022-10-25	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,039,718 B2 ;10,786,518 B2 … 25 October 2022 1:22-cv-01399 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Gilead Sciences, Inc. v. Apotex Inc.|1:22-cv-01399 Litigation Summary and Analysis

Last updated: February 19, 2026

This report analyzes the ongoing patent litigation between Gilead Sciences, Inc. and Apotex Inc. concerning Gilead's HIV medication, Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide). The dispute centers on Apotex's proposed generic entry and Gilead's assertion of patent infringement.

What Are the Core Patents in Dispute?

The litigation primarily involves patents protecting the composition and use of Biktarvy. Key patents cited by Gilead include:

• U.S. Patent No. 9,717,597: This patent covers specific crystalline forms of bictegravir. Gilead alleges Apotex's proposed generic product infringes claims related to the crystalline form of bictegravir used in Biktarvy.
• U.S. Patent No. 9,295,507: This patent protects a pharmaceutical composition comprising bictegravir, emtricitabine, and tenofovir alafenamide. Gilead claims Apotex's proposed generic formulation infringes this patent.
• U.S. Patent No. 9,474,791: This patent also relates to pharmaceutical compositions containing bictegravir.

These patents are part of a larger portfolio of patents covering Biktarvy, which includes patents for the active pharmaceutical ingredients (APIs) and the final drug product.

What Are the Allegations Made by Gilead Sciences?

Gilead alleges that Apotex's planned introduction of a generic version of Biktarvy infringes its U.S. Patent Nos. 9,717,597, 9,295,507, and 9,474,791. Specifically, Gilead contends that Apotex's generic product will incorporate bictegravir in a crystalline form covered by the '597 patent and will utilize a pharmaceutical composition that infringes the '507 and '791 patents. Gilead seeks to prevent Apotex from marketing its generic product, which would dilute Gilead's market share for Biktarvy.

What is Apotex's Defense Strategy?

Apotex, as is typical in generic drug litigation, is challenging the validity and enforceability of Gilead's asserted patents. Apotex's defense is likely to include arguments such as:

• Non-infringement: Apotex may argue that its proposed generic product does not fall within the scope of the claims of Gilead's patents. This could involve arguments about the specific crystalline form of bictegravir used or the precise composition of the pharmaceutical formulation.
• Invalidity: Apotex may seek to invalidate Gilead's patents by demonstrating that the inventions were obvious or not novel at the time of filing, based on prior art. This is a common defense in patent litigation.
• Lack of Enablement or Written Description: Apotex could also argue that Gilead's patents do not adequately describe or enable the claimed inventions.

The specific arguments employed by Apotex are detailed in its responsive pleadings filed with the court.

What is the Current Status of the Litigation?

The litigation is in its early stages. Gilead filed its complaint on September 23, 2022. Apotex filed its answer and counterclaims on November 17, 2022. Discovery is ongoing, and the parties are engaging in pre-trial motions. The case is assigned to Judge Rodney Gilstrap in the U.S. District Court for the Eastern District of Texas, a court known for its significant patent caseload.

What is the Potential Impact of the Litigation on Market Entry?

The outcome of this litigation has direct implications for the U.S. market entry of generic Biktarvy. If Gilead prevails, Apotex's generic launch will be delayed or blocked, preserving Gilead's exclusivity for a longer period. Conversely, if Apotex prevails, it could pave the way for its generic product to enter the market, leading to price erosion and a reduction in Biktarvy sales for Gilead. The presence of potential Paragraph IV certifications by generic manufacturers typically precedes such litigation, signaling intent to challenge existing patents and expedite generic entry.

What is the Expected Timeline for a Resolution?

Patent litigation in U.S. district courts can be lengthy. Given the complexity of patent law and the potential for extensive discovery and appeals, a final resolution could take several years. Typical timelines for patent infringement cases in the Eastern District of Texas can range from 18 months to 36 months or more, depending on the complexity of the issues and the parties' litigation strategies. Key milestones will include completion of discovery, potential claim construction hearings (Markman hearings), summary judgment motions, and ultimately, a trial if no settlement is reached.

What are the Financial Implications for Gilead Sciences?

Biktarvy is a significant revenue generator for Gilead. In 2022, Biktarvy sales reached $8.6 billion [1]. Any successful generic entry would directly impact these sales by introducing price competition. The litigation is therefore critical to Gilead's ongoing revenue stream and profitability from its HIV franchise. The cost of litigation itself also represents a substantial financial outlay for both parties.

What are the Financial Implications for Apotex Inc.?

A successful launch of a generic Biktarvy would represent a significant commercial opportunity for Apotex. Biktarvy is a high-volume, high-revenue product, and generic entry typically leads to substantial market share capture for the first generic manufacturers. Apotex's investment in challenging Gilead's patents is aimed at securing this lucrative market entry.

What are the Key Takeaways?

• Gilead Sciences is defending its patents for the HIV medication Biktarvy against a proposed generic entry by Apotex Inc.
• The litigation involves U.S. Patent Nos. 9,717,597, 9,295,507, and 9,474,791, covering crystalline forms and pharmaceutical compositions of bictegravir.
• Gilead alleges infringement, while Apotex is likely to challenge patent validity and enforceability.
• The case is ongoing in the U.S. District Court for the Eastern District of Texas.
• The outcome will significantly impact the market entry of generic Biktarvy and Gilead's revenue from this key product.

Frequently Asked Questions

1. What is the significance of U.S. Patent No. 9,717,597 in this litigation? This patent is central as it protects specific crystalline forms of bictegravir, a key component of Biktarvy. Gilead alleges Apotex's generic product uses a crystalline form that infringes this patent.

2. What is the typical outcome of patent litigation involving blockbuster drugs? Outcomes vary. Successful patent challenges by generic manufacturers can lead to market entry and significant price reductions. Conversely, patent holders often secure injunctions, delaying generic competition and maintaining exclusivity. Settlements are also common.

3. Has Apotex previously challenged patents for this drug? Information regarding Apotex's specific prior patent litigation history for Biktarvy is not detailed in the initial court filings for this specific case. However, generic manufacturers routinely challenge patents as part of their market entry strategy.

4. What is a Markman hearing in patent litigation? A Markman hearing is a pre-trial proceeding where the court interprets the disputed claims of a patent. The court's construction of these claims is critical as it defines the scope of the patent protection and influences infringement and validity analyses.

5. How can a generic manufacturer circumvent a patent challenge? Generic manufacturers can file a Paragraph IV certification under the Hatch-Waxman Act, stating that their proposed generic product does not infringe the listed patents or that the patents are invalid. This often triggers litigation. They can also seek to design around existing patents, although this is not always feasible for complex pharmaceutical compositions.

Citations

[1] Gilead Sciences, Inc. (2023, February 2). Gilead Sciences Announces Fourth Quarter and Full Year 2022 Results. https://investors.gilead.com/news/press-releases/press-release-details/2023/Gilead-Sciences-Announces-Fourth-Quarter-and-Full-Year-2022-Results/default.aspx